Institution
Beaumont Health
Nonprofit•Royal Oak, Michigan, United States•
About: Beaumont Health is a nonprofit organization based out in Royal Oak, Michigan, United States. It is known for research contribution in the topics: Medicine & Population. The organization has 1483 authors who have published 1448 publications receiving 15407 citations. The organization is also known as: William Beaumont Health System & Beaumont Hospitals.
Topics: Medicine, Population, Cancer, Breast cancer, Arthroplasty
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Observations on a child with a distinctive constellation of clinical features including macrocerebellum, epilepsy, apparent intellectual disability, dysautonomia, gut malrotation, and poor gut motility highlight a potential genetic cause of this rare disorder and raise the possibility that one or more gene(s) in the 16.1–q24.2 interval regulate cerebellar development.
Abstract: Macrocerebellum is a rare condition characterized by enlargement of the cerebellum with conservation of the overall shape and cytoarchitecture. Here, we report on a child with a distinctive constellation of clinical features including macrocerebellum, epilepsy, apparent intellectual disability, dysautonomia, gut malrotation, and poor gut motility. Oligonucleotide chromosome microarray analysis identified a 16q24.1-q24.2 deletion that included four OMIM genes (FBXO31, MAP1LC3B, JPH3, and SLC7A5). Review of prior studies describing individuals with similar or overlapping16q24.1-q24.2 deletions identified no other reports of macrocerebellum. These observations highlight a potential genetic cause of this rare disorder and raise the possibility that one or more gene(s) in the 16q24.1-q24.2 interval regulate cerebellar development.
8 citations
••
TL;DR: Echocardiography is the leading tool to evaluate post TAVR transaortic valve mean gradients (MG) and pressure recovery beyond the AV leads to lower and in some cases, markedly discrepant catheterization (CATH) vs. (ECHO) MG in patients with aortic stenosis.
8 citations
••
TL;DR: RT-LAMP is used for ZIKV detection in various biological samples within 30 min, without first isolating the RNA from the sample, to allow for a more efficient and low-cost testing without the need for expensive equipment.
Abstract: Infection with Zika virus (ZIKV) can be asymptomatic in adults, however, infection during pregnancy can lead to miscarriage and severe neurological birth defects. The goal of this protocol is to quickly detect ZIKV in both human and mosquito samples. The current gold standard for ZIKV detection is quantitative reverse transcription PCR (qRT-PCR); reverse transcription loop-mediated isothermal amplification (RT-LAMP) may allow for a more efficient and low-cost testing without the need for expensive equipment. In this study, RT-LAMP is used for ZIKV detection in various biological samples within 30 min, without first isolating the RNA from the sample. This technique is demonstrated using ZIKV infected patient urine and serum, and infected mosquito samples. 18S ribosomal ribonucleic acid and actin are used as controls in human and mosquito samples, respectively.
8 citations
••
TL;DR: Main clinical features were a submucous cleft palate with persistent VPI after palatoplasty, an ectopic left internal carotid artery and a prominent aortic root.
8 citations
••
TL;DR: Treatment of newly diagnosed GBM with PRT is feasible and produces promising effectiveness while maintaining neurocognitive function and QOL, and validation of the results in a larger prospective trial warrants consideration.
Abstract: BACKGROUND Pulsed radiation therapy (PRT) has shown effective tumor control and superior normal-tissue sparing ability compared with standard radiotherapy (SRT) in preclinical models and retrospective clinical series. This is the first prospective trial to investigate PRT in the treatment of patients with newly diagnosed glioblastoma (GBM). METHODS This is a single-arm, prospective study. Patients with newly diagnosed GBM underwent surgery, followed by 60 Gy of PRT with concurrent temozolomide (TMZ). Each day, a 2-Gy fraction was divided into ten 0.2-Gy pulses, separated by 3-minute intervals. Patients received maintenance TMZ. Neurocognitive function (NCF) and quality of life (QoL) were monitored for 2 years using the Hopkins Verbal Learning Test‒Revised and the European Organisation for Research and Treatment of Cancer QLQ-C30 QoL questionnaire. Change in NCF was evaluated based on a minimal clinically important difference (MCID) threshold of 0.5 standard deviation. RESULTS Twenty patients were enrolled with a median follow-up of 21 months. Median age was 60 years. Forty percent underwent subtotal resection, and 60% underwent gross total resection. One patient had an isocitrate dehydrogenase (IDH)-mutated tumor. Median progression-free survival (PFS) and overall survival (OS) were 10.7 and 20.9 months, respectively. In a post-hoc comparison, median OS for the prospective cohort was longer, compared with a matched cohort receiving SRT (20.9 vs 14 mo, P = 0.042). There was no decline in QoL, and changes in NCF scores did not meet the threshold of an MCID. CONCLUSIONS Treatment of newly diagnosed GBM with PRT is feasible and produces promising effectiveness while maintaining neurocognitive function and QoL. Validation of our results in a larger prospective trial warrants consideration.
8 citations
Authors
Showing all 1494 results
Name | H-index | Papers | Citations |
---|---|---|---|
Barry P. Rosen | 102 | 529 | 36258 |
Praveen Kumar | 88 | 1339 | 35718 |
George S. Wilson | 88 | 716 | 33034 |
Ahmed Ali | 61 | 728 | 15197 |
Di Yan | 61 | 295 | 11437 |
David P. Wood | 59 | 243 | 12154 |
Brian D. Kavanagh | 58 | 322 | 15865 |
James A. Goldstein | 49 | 193 | 12312 |
Kenneth M. Peters | 46 | 197 | 6513 |
James M. Robbins | 45 | 157 | 8489 |
Bin Nan | 44 | 139 | 5321 |
Inga S. Grills | 43 | 217 | 6343 |
Sachin Kheterpal | 43 | 169 | 8545 |
Craig W. Stevens | 42 | 164 | 6598 |
Thomas Guerrero | 41 | 93 | 5018 |